Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
New insights into COVID-19 infectiousness
Fri August 19th - British researchers have unveiled the first real-world study to estimate how long people are infectious with mild COVID-19. More
Gene variant that protects against heart disease
Fri August 19th - A gene variant has been identified that helps to protect against heart diseases. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Development of new antibiotics is 'stagnant'

Friday June 24th 2022

Work to develop new antibiotics is ‘stagnant’ and does not meet global needs, a new report from the World Health Organization has warned.

The 2021 annual report says since 2017 only 12 antibiotics have been approved, 10 of which belong to existing classes with established mechanisms of antimicrobial resistance (AMR).

In 2021 there were 27 new antibiotics in clinical development against priority pathogens – down from 31 products in 2017 – while the number of products in the preclinical stage has remained constant over the past three years.

Dr Hanan Balkhy, WHO assistant director general on AMR, said: “There is a major gap in the discovery of antibacterial treatments, and more so in the discovery of innovative treatments.

“This presents a serious challenge to overcoming the escalating pandemic of antimicrobial resistance and leaves every one of us increasingly vulnerable to bacterial infections including the simplest infections.”

The report says of the 77 anti-bacterial agents in clinical development, 45 are ‘traditional’ direct-acting small molecules and 32 are ‘non-traditional’ agents.

It takes about 10-15 years to progress an antibiotic candidate from the preclinical to the clinical stages and for antibiotics in existing classes, on average, one of every 15 drugs in preclinical development reaches patients. For new classes of antibiotics, one in 30 candidates reaches patients.

Of the 27 antibiotics in the clinical pipeline that address priority pathogens, six fulfil at least one of WHO’s criteria for innovation.

Dr Haileyesus Getahun, WHO director of AMR global coordination, warned that time is running out to get ahead of antimicrobial resistance.

“The pace and success of innovation is far below what we need to secure the gains of modern medicine against age-old but devastating conditions like neonatal sepsis,” he added.

The COVID-19 pandemic has also hampered progress, delayed clinical trials, and diverted attention of the already limited investors, but most of the innovation in antibiotics is driven by small- and medium-sized companies and they are struggling to find investors to finance late-stage clinical development up to regulatory approval.

Tags: MRSA & Hygiene | Pharmaceuticals | World Health

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)